Table 2.
Relationship between expression levels of WT1 and clinical and pathological features of the NSCLC individuals
| Clinical Characteristics | Non-increased (ΔΔCt ≤ 1) n = 27 |
Increased (ΔΔCt > 1) n = 33 |
Test of Significance |
|---|---|---|---|
| Sex | |||
| Female | 9 (15.00%) | 12 (20.00%) | χ2 = 0.0599 |
| Male | 18 (30.00%) | 21 (35.00%) | P = 0.8066 |
| Age | |||
| < 60 | 15 (25.00%) | 21 (35.00%) | χ2 = 0.4040 |
| >=60 | 12 (20.00%) | 12 (20.00%) | P = 0.5250 |
| Tumour Type | |||
| Squamous cell lung carcinoma | 11 (18.33%) | 14 (23.33%) | |
| Lung adenocarcinoma | 16 (26.67%) | 17 (28.33%) | χ2 = 1.8084 |
| Others | 0 (0.00%) | 2 (3.33%) | P = 0.5825 F |
| T Stage | |||
| T1 | 18 (30.00%) | 9 (15.00%) | χ2 = 9.3113 |
| T2 + T3 | 9 (15.00%) | 24 (40.00%) | P = 0.0023 |
| N Stage | |||
| N0 | 18 (30.00%) | 13 (21.67%) | χ2 = 4.4231 |
| N1 + N2 | 9 (15.00%) | 20 (33.33%) | P = 0.0355 |
| Tumour Grade | |||
| I + II | 22 (36.67%) | 17 (28.33%) | χ2 = 5.8615 |
| III + IV | 5 (8.33%) | 16 (26.67%) | P = 0.0155 |
| Differentiation | |||
| Well | 6 (10.00%) | 8 (13.33%) | |
| Moderate | 14 (23.33%) | 19 (31.67%) | χ2 = 0.5255 |
| Poor | 7 (11.67%) | 6 (10.00%) | P = 0.7689 |
F: Fisher’s exact test